*together with Prosperity Pub & Behind the Markets
Good day, 360!
Here are some of our top movers today. And give Jeff’s interview with Nate Tucci a view— you WON’T regret it. Despite light attendance, fantastic OPT-IN rate. Why? Because the ORANGE LINE is the only thing that makes sense right now ?.
FOCUS LIST?
VRPX – Up over 28% in the pre-market after announcing positive results in human study for its molecular envelope technology
ORGO – Up over 12% in pre after announcing better than expected earnings
BTAI – Up over 37% in pre after announcing regaining of compliance with Nasdaq minimum bid price rule
*together with Prosperity Pub
Why is everyone fighting over the BLUE line during the day?
Consider the ORANGE line.
See how this OBSESSED mathematical trader puts trades on (& targets) at Market Close over and over again…
*orange line shows trades bought at the Close and exited by the Open since 1993! Whoa!
Learn how to trade the ORANGE line with Nate Tucci.
HOTLIST?
VRPX – Up over 28% in the pre-market after announcing positive results in human study for its molecular envelope technology
Virpax Pharmaceuticals Inc. (VRPX) is a preclinical-stage pharmaceutical company that develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders.
In the after-hours yesterday, the company announced the completion of a human study using the Molecular Envelope Technology (MET) and showing no moderate to severe adverse events. Virpax uses MET in its Envelta (NES100) and NobrXiol.
Envelta is an enkephalin drug product based on a type of nanotechnology delivery approach. The MET is designed to protect and help carry the drug to the brain with the goal of promptly suppressing pain by binding to the delta opioid receptors.
Envelta has demonstrated analgesic potential in animal models without the development of opioid tolerance or reward seeking behavior.
Shares of VRPX traded up over 28% in the pre-market in reaction to the news.
The $0.26 area acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $0.28, $0.30, $0.32, $0.33, $0.34, $0.36 and then the pre-market high at $0.41. Beyond that $0.47 and $0.5150 come into play.
Below $0.26, targets to the downside are $0.25 and then a gap fill at $0.2272.
ORGO – Up over 12% in pre after announcing better than expected earnings
Organogenesis Holdings Inc. (ORGO) is a regenerative medicine company that develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States.
In the after-hours yesterday, the company reported fourth quarter 2024 financial results.
Highlights Include:
Net revenue of $126.7 million for the fourth quarter of 2024, an increase of $27.0 million compared to net revenue of $99.7 million for the fourth quarter of 2023.
Net income of $7.7 million for the fourth quarter of 2024, compared to net loss of $0.6 million for the fourth quarter of 2023, an increase in net income of $8.3 million.
Adjusted EBITDA of $18.2 million for the fourth quarter of 2024, compared to Adjusted EBITDA of $7.5 million for the fourth quarter of 2023, an increase of $10.7 million.
Adjusted net income of $8.8 million for the fourth quarter of 2024, compared to adjusted net income of $1.9 million for the fourth quarter of 2023, an increase of $6.8 million.
Shares of ORGO traded up over 12% in the pre-market in reaction to the results.
The first target for bulls is prior pre-market resistance at $3.80 and then the pre-market high at $4.04. Beyond that, $4.20 and $4.57 come into play.
Below $3.80, targets to the downside are $3.50, $3.40, $3.30 and then a gap fill at $3.07.
BTAI – Up over 37% in pre after announcing regaining of compliance with Nasdaq minimum bid price rule
BioXcel Therapeutics Inc. (BTAI) is a commercial-stage biopharmaceutical company that engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.
In the pre-market this morning, the company announced that it has received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2).
As previously disclosed, on September 16, 2024, the Company was notified by Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. To regain compliance, the Company was required to maintain a minimum closing bid price of $1.00 per share for at least 12 consecutive trading days. This requirement was met on February 26, 2025.
Shares of BTAI traded up over 37% in the pre-market in reaction to the news.
The $2.29 area was prior resistance and now becomes a potential level of support.
Above it, targets to the upside are $2.56, $2.65 and then the pre-market high at $2.75. Beyond $2.75, targets to the upside are $3, $3.15, $3.82 and $4.78.
Below $2.29, targets to the downside are $2.20, $2, $1.85 and then a gap fill at $1.73.
MARKET NEWS ?
DISCLAIMER: To more fully understand any Ragingbull.com, LLC (“RagingBull”) subscription, website, application or other service (“Services”), please review our full disclaimer located at https://ragingbull.com/disclaimer
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers’ trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers.
RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.
*Sponsored Content: If you purchase anything through a link in this email other than RagingBull (RB) services, you should assume that we have an affiliate relationship with the company providing the product that you purchase, and that we will be paid in some way. RB is not responsible for any content hosted on affiliate’s sites and it is the affiliate’s responsibility to ensure compliance with applicable laws. We recommend that you do your own independent research before purchasing anything. While we believe in the companies we form affiliate relationships with, please don’t spend any money on these products unless you believe they will help you achieve your goals.
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.
#Todays #top #stories #pain #management #innovation #revenue #jumps